This case report details an uncommon instance of Langerhans cell histiocytosis (LCH) in a neonate, manifesting as a cutaneous lesion on the eyelid. Research indicates that LCH is characterized by an overabundance of immune cells, which may lead to tumor formation, exhibiting a range of severity. In this instance, the illness appears to have been moderate, without systemic involvement, and resolved spontaneously without intervention, despite a genetic mutation associated with severe manifestations. The evidence suggests a favorable prognosis for this skin-limited congenital LCH, although eyelid involvement in neonates is uncommon.
CollinM, BigleyV, McClainKL, AllenCE.Cell(s) of origin of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):825–838.
2.
PDQ Pediatric Treatment Editorial Board. Langerhans cell histiocytosis treatment (PDQ®): health professional version. 2015Sep25. In: PDQ Cancer Information Summaries[Internet]. Bethesda (MD): National Cancer Institute (US); 2002. Available from:https://www.ncbi.nlm.nih.gov/books/NBK65799.2/
3.
ZwerdlingT, KoniaT, SilversteinM.Congenital, single system, single site, Langerhans cell histiocytosis: a new case, observations from the literature, and management considerations. Pediatr Dermatol. 2009;26(1):121–126.
4.
LoC, PatelP, CharlesNC.Langerhans cell histiocytosis presenting as a nodulo-ulcerative eyelid lesion. Ophthalmic Plast Reconstr Surg. 2017;33(3S Suppl. 1):S51–S52. doi: 10.1097/IOP.0000000000000555
5.
HéritierS, EmileJF, BarkaouiMA, . BRAF mutation correlates with high risk Langerhans cell histiocytosis and increased resistance to first line therapy. J Clin Oncol. 2016;34(25):3023–3030.
NannD, SchneckenburgerP, SteinhilberJ, . Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae. Ann Hematol. 2019;98(7):1617–1626.
